Omeros granted CMS pass-through reimbursement status for Omidria

The Center for Medicare and Medicaid Services has granted Omeros Corporation with transitional pass-through status for Omidria 1%/0.3%, according to an Omeros press release.This status — effective Jan. 1, 2015 — will allow ambulatory surgery centers and other outpatient facilities to bill Medicare and other insurance providers for the phenylephrine and ketorolac injection using a temporary Healthcare Common Procedure Coding System code unique to Omidria, according to the release.